| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
15,346 |
14,027 |
$803K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,587 |
4,300 |
$328K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
10,057 |
9,815 |
$297K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,491 |
2,352 |
$183K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,284 |
2,245 |
$177K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,178 |
2,144 |
$169K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,447 |
1,440 |
$124K |
| 92552 |
|
3,160 |
2,992 |
$40K |
| 90461 |
|
2,068 |
2,006 |
$25K |
| 92081 |
|
1,541 |
1,455 |
$19K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,226 |
1,172 |
$16K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
792 |
561 |
$15K |
| 96160 |
|
5,180 |
4,731 |
$12K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
370 |
362 |
$12K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
228 |
221 |
$11K |
| 86328 |
|
247 |
243 |
$10K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
402 |
398 |
$10K |
| 99441 |
|
122 |
113 |
$3K |
| 99174 |
|
319 |
313 |
$2K |
| 0071A |
|
22 |
22 |
$1K |
| 99215 |
Prolong outpt/office vis |
13 |
12 |
$1K |
| 69210 |
|
29 |
25 |
$983.83 |
| 90480 |
|
43 |
42 |
$917.65 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
41 |
39 |
$640.78 |
| 0011A |
|
12 |
12 |
$480.40 |
| 99442 |
|
16 |
16 |
$331.65 |
| 90698 |
|
1,162 |
1,072 |
$92.47 |
| 96127 |
|
16 |
16 |
$74.88 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
66 |
54 |
$58.29 |
| 81002 |
|
14 |
13 |
$42.71 |
| 90686 |
|
3,648 |
3,138 |
$19.89 |
| 94760 |
|
23 |
15 |
$15.84 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
41 |
39 |
$4.02 |
| 90656 |
|
603 |
546 |
$0.00 |
| 90744 |
|
116 |
106 |
$0.00 |
| 90680 |
|
294 |
271 |
$0.00 |
| 90716 |
|
79 |
78 |
$0.00 |
| 90651 |
|
39 |
39 |
$0.00 |
| 90633 |
|
55 |
54 |
$0.00 |
| 90670 |
|
1,053 |
973 |
$0.00 |
| G9920 |
Screening performed and negative |
186 |
177 |
$0.00 |
| 90685 |
|
114 |
93 |
$0.00 |
| 90655 |
|
148 |
138 |
$0.00 |
| 90707 |
|
107 |
100 |
$0.00 |
| 90734 |
|
27 |
27 |
$0.00 |